Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dialyzer aims to cut down on dialysis symptoms

NCT ID NCT06032208

Symptom relief Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a new type of dialyzer, called Theranova, can help reduce common symptoms like pain, fatigue, and poor sleep in people with end-stage renal disease who are on dialysis. About 100 participants will use their usual dialyzer for the first 4 weeks and then switch to the Theranova dialyzer for 24 weeks, reporting their symptoms through a simple app. The goal is to see if removing larger toxins from the blood improves how patients feel.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Theranova dialyzer (a device used during hemodialysis to remove larger toxins)
What this could lead to
If it works, this could lead to better symptom management and improved quality of life for people on dialysis.
What could go wrong
This is a small, early-stage extension study with no control group, so results may not be conclusive. The new dialyzer may not significantly improve symptoms compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Conventional thrice weekly HD schedule * Must be on chronic hemodialysis for at least 3 months * Age ≥18 years * Willing and able to give informed consent Exclusion Criteria: * Active infection (may enroll once infection is cleared) * Patients receiving daily hemodialysis treatment * Patients currently receiving Hemodiafiltration (HDF), Hemofiltration (HF) or Isolated ultrafiltration (ISO UF) more than once in three months * Visual impairment * History of neurocognitive impairment * History of stroke (CVA)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage renal disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • QEII Health Sciences Centre, Nova Scotia Health

    RECRUITING

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Seven Oaks Hospital Chronic Disease Innovation Centre Inc. (CDIC)

    RECRUITING

    Winnipeg, Manitoba, R2V 3M3, Canada

  • Victoria Hospital, London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A 5W9, Canada

  • Westmount Kidney Care Centre

    RECRUITING

    London, Ontario, N6K 1M6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.